EP2467481A4 - Behandlung von sirtuin (sirt)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein sirtuin (sirt) - Google Patents

Behandlung von sirtuin (sirt)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein sirtuin (sirt)

Info

Publication number
EP2467481A4
EP2467481A4 EP10802960A EP10802960A EP2467481A4 EP 2467481 A4 EP2467481 A4 EP 2467481A4 EP 10802960 A EP10802960 A EP 10802960A EP 10802960 A EP10802960 A EP 10802960A EP 2467481 A4 EP2467481 A4 EP 2467481A4
Authority
EP
European Patent Office
Prior art keywords
sirt
sirtuin
inhibition
treatment
related diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10802960A
Other languages
English (en)
French (fr)
Other versions
EP2467481A2 (de
Inventor
Joseph Collard
Sherman Olga Khorkova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curna Inc
Original Assignee
Curna Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/066445 external-priority patent/WO2010065662A2/en
Priority claimed from PCT/US2010/026119 external-priority patent/WO2010102058A2/en
Application filed by Curna Inc filed Critical Curna Inc
Priority to EP15180289.9A priority Critical patent/EP2985348B1/de
Priority claimed from PCT/US2010/043075 external-priority patent/WO2011011700A2/en
Publication of EP2467481A2 publication Critical patent/EP2467481A2/de
Publication of EP2467481A4 publication Critical patent/EP2467481A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10802960A 2009-07-24 2010-07-23 Behandlung von sirtuin (sirt)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein sirtuin (sirt) Withdrawn EP2467481A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15180289.9A EP2985348B1 (de) 2009-07-24 2010-07-23 Behandlung von sirtuin 6 (sirt6)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt6

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22839209P 2009-07-24 2009-07-24
US25907209P 2009-11-06 2009-11-06
PCT/US2009/066445 WO2010065662A2 (en) 2008-12-04 2009-12-02 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
PCT/US2010/026119 WO2010102058A2 (en) 2009-03-04 2010-03-03 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
US33042710P 2010-05-03 2010-05-03
PCT/US2010/043075 WO2011011700A2 (en) 2009-07-24 2010-07-23 Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP15180289.9A Division EP2985348B1 (de) 2009-07-24 2010-07-23 Behandlung von sirtuin 6 (sirt6)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt6

Publications (2)

Publication Number Publication Date
EP2467481A2 EP2467481A2 (de) 2012-06-27
EP2467481A4 true EP2467481A4 (de) 2013-01-16

Family

ID=46124982

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10802960A Withdrawn EP2467481A4 (de) 2009-07-24 2010-07-23 Behandlung von sirtuin (sirt)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein sirtuin (sirt)
EP15180289.9A Active EP2985348B1 (de) 2009-07-24 2010-07-23 Behandlung von sirtuin 6 (sirt6)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt6

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP15180289.9A Active EP2985348B1 (de) 2009-07-24 2010-07-23 Behandlung von sirtuin 6 (sirt6)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt6

Country Status (3)

Country Link
EP (2) EP2467481A4 (de)
ES (1) ES2854004T3 (de)
HK (1) HK1219758A1 (de)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027332A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
US20050136395A1 (en) * 2003-05-08 2005-06-23 Affymetrix, Inc Methods for genetic analysis of SARS virus
WO2006006171A2 (en) * 2004-07-14 2006-01-19 Gamida-Cell Ltd. Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the sir2 family of enzymes
WO2006069592A2 (en) * 2004-12-31 2006-07-06 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Method for diagnosing an/or predicting preeclampsia and/or related disorders
EP1757306A1 (de) * 2004-04-09 2007-02-28 Genecare Research Institute Co., Ltd Mittel zur auslösung von karzinomzell-spezifischer apoptose mit einem gen als ziel; das für die chromosomenstabilisierung relevant ist
US20080108583A1 (en) * 2006-01-20 2008-05-08 Elena Feinstein Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
JP2008195673A (ja) * 2007-02-14 2008-08-28 Nippon Meat Packers Inc 延命効果物質、および感染防御効果・ワクチン効果促進物質、前記物質の検定用コンストラクト、並びにそれらの用途
WO2009140562A1 (en) * 2008-05-15 2009-11-19 Sirtris Pharmaceuticals, Inc. Sirt1 polymorphic variants and methods of use thereof
WO2010065662A2 (en) * 2008-12-04 2010-06-10 Curna, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090996A1 (en) * 2004-03-15 2005-09-29 Regeneron Pharmaceuticals, Inc. Sirt6 transgenic non-human animals and assay methods
WO2005110464A2 (en) * 2004-05-14 2005-11-24 Oregon Health & Science University Irx5 inhibition as treatment for hyperproliferative disorders

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027332A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
US20050136395A1 (en) * 2003-05-08 2005-06-23 Affymetrix, Inc Methods for genetic analysis of SARS virus
EP1757306A1 (de) * 2004-04-09 2007-02-28 Genecare Research Institute Co., Ltd Mittel zur auslösung von karzinomzell-spezifischer apoptose mit einem gen als ziel; das für die chromosomenstabilisierung relevant ist
WO2006006171A2 (en) * 2004-07-14 2006-01-19 Gamida-Cell Ltd. Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the sir2 family of enzymes
WO2006069592A2 (en) * 2004-12-31 2006-07-06 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Method for diagnosing an/or predicting preeclampsia and/or related disorders
US20080108583A1 (en) * 2006-01-20 2008-05-08 Elena Feinstein Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
JP2008195673A (ja) * 2007-02-14 2008-08-28 Nippon Meat Packers Inc 延命効果物質、および感染防御効果・ワクチン効果促進物質、前記物質の検定用コンストラクト、並びにそれらの用途
WO2009140562A1 (en) * 2008-05-15 2009-11-19 Sirtris Pharmaceuticals, Inc. Sirt1 polymorphic variants and methods of use thereof
WO2010065662A2 (en) * 2008-12-04 2010-06-10 Curna, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
A. BONAUER ET AL: "Supporting Online Material for MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice", SCIENCE, 21 May 2009 (2009-05-21), pages 1 - 35, XP055042749, Retrieved from the Internet <URL:http://www.sciencemag.org/content/suppl/2009/05/21/1174381.DC1/Bonauer_SOM.pdf> [retrieved on 20121031] *
APARNA PURUSHOTHAM ET AL: "Hepatocyte-Specific Deletion of SIRT1 Alters Fatty Acid Metabolism and Results in Hepatic Steatosis and Inflammation", CELL METABOLISM, vol. 9, no. 4, 8 April 2009 (2009-04-08), pages 327 - 338, XP055039151, ISSN: 1550-4131, DOI: 10.1016/j.cmet.2009.02.006 *
BONAUER ANGELIKA ET AL: "MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 324, no. 5935, 21 May 2009 (2009-05-21), pages 1710 - 1713, XP002575234, ISSN: 0036-8075 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 2008 (2008-10-01), KUEHBACHER ANGELIKA ET AL: "MicroRNA 92a Controls Vessel Growth And Functional Recovery After Ischemia", XP002684082, Database accession no. PREV200900197869 *
DATABASE Geneseq [online] 30 October 2008 (2008-10-30), "Human SIRT1 gene HA044263-F RT-PCR primer, SEQ ID NO:10.", retrieved from EBI accession no. GSN:ATF64186 Database accession no. ATF64186 *
DATABASE Geneseq [online] 30 October 2008 (2008-10-30), "Human SIRT1 gene HA044263-R RT-PCR primer, SEQ ID NO:11.", retrieved from EBI accession no. GSN:ATF64187 Database accession no. ATF64187 *
DATABASE Geneseq [online] 4 October 2007 (2007-10-04), "SARS coronavirus related nucleic acid probe SEQ ID NO 83591.", retrieved from EBI accession no. GSN:AFA01179 Database accession no. AFA01179 *
MUNEKAZU YAMAKUCHI ET AL: "miR-34a repression of SIRT1 regulates apoptosis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 105, no. 36, 9 September 2008 (2008-09-09), pages 13421 - 13426, XP008149911, ISSN: 0027-8424, [retrieved on 20080828], DOI: 10.1073/PNAS.0801613105 *
SMALHEISER N R ET AL: "Natural antisense transcripts are co-expressed with sense mRNAs in synaptoneurosomes of adult mouse forebrain", NEUROSCIENCE RESEARCH, ELSEVIER, SHANNON, IR, vol. 62, no. 4, 1 December 2008 (2008-12-01), pages 236 - 239, XP025669354, ISSN: 0168-0102, [retrieved on 20080904], DOI: 10.1016/J.NEURES.2008.08.010 *
SUN ET AL: "Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 58, no. 1, 14 September 2007 (2007-09-14), pages 21 - 29, XP022242948, ISSN: 0169-5002, DOI: 10.1016/J.LUNGCAN.2007.05.013 *
THIMMAPPA S. ANEKONDA ET AL: "Neuronal protection by sirtuins in Alzheimer's disease", JOURNAL OF NEUROCHEMISTRY, vol. 96, no. 2, 1 January 2006 (2006-01-01), pages 305 - 313, XP055039113, ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.2005.03492.x *
WAHLESTEDT ET AL: "Natural antisense and noncoding RNA transcripts as potential drug targets", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 11, no. 11-12, 1 June 2006 (2006-06-01), pages 503 - 508, XP027889295, ISSN: 1359-6446, [retrieved on 20060601] *

Also Published As

Publication number Publication date
EP2467481A2 (de) 2012-06-27
HK1219758A1 (zh) 2017-04-13
EP2985348A3 (de) 2016-04-20
ES2854004T3 (es) 2021-09-20
EP2985348B1 (de) 2020-12-30
EP2985348A2 (de) 2016-02-17

Similar Documents

Publication Publication Date Title
HK1217031A1 (zh) 通過抑制 的天然的反義轉錄物來對 相關疾病所進行的治療
HK1217729A1 (zh) 通過對天然反義轉錄到 的抑制治療組蛋白去乙酰化酶 相關疾病
EP2427552A4 (de) Behandlung von tristetraprolin (ttp)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ttp
EP2352830A4 (de) Behandlung von krankheiten in verbindung mit apolipoprotein a1 durch hemmung eines natürlichen antisense-transkripts gegen apolipoprotein a1
EP2370580A4 (de) Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
EP2427554A4 (de) Behandlung von dystrophin-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen die dmd-familie
EP2443237A4 (de) Behandlung von krankheiten im zusammenhang mit dem kollagengen durch hemmung des natürlichen antisense-transkripts zu einem kollagengens
EP2432881A4 (de) Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
EP2630241A4 (de) Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua
EP2446037A4 (de) Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
EP2585596A4 (de) Behandlung von scna-vermittelten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen scna
EP2718439A4 (de) Behandlung von frataxin (fxn)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen fxn
EP2521785A4 (de) Behandlung von krankheiten im zusammenhang mit pankreasentwicklungsgenen durch hemmung des natürlichen antisense-transkripts zu einem pankreasentwicklungsgen
EP2435571A4 (de) Behandlung von durch antivirale gene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein antivirales gen
EP2519633A4 (de) Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1
HK1219111A1 (zh) 通過抑制&#39; -相互作用蛋白的 末端&#39; 的天然反義轉錄物而治療 相關疾病
HK1221914A1 (zh) 通過抑制針對腦衍生神經營養因子 的天然反義轉錄物來治療 相關的疾病
EP2513310A4 (de) Behandlung von erkrankungen im zusammenhang mit dem membranengebundenen transkriptionsfaktor-peptidase-ort 1 (mbtps1) mittels hemmung des natürlichen antisense-transkripts gegen mbtps1
EP2625274A4 (de) Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
EP2516648A4 (de) Behandlung von erkrankungen im zusammenhang mit dem häpatozyten-wachstumsfaktor (hgf) mittels hemmung des natürlichen antisense-transkripts gegen hgf
EP2370579A4 (de) Behandlung von erythropoetin (epo)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen epo
EP2539452A4 (de) Behandlung von durch pyrrolin-5-carboxylat-reduktase 1 (pycr1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für pycr1
EP2443238A4 (de) Behandlung von erkrankungen im zusammenhang mit paraoxonase 1 (pon1) mittels hemmung des natürlichen antisense-transkripts gegen pon 1
EP2569432A4 (de) Behandlung von par4-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen par4
EP2464731A4 (de) Behandlung von adiponectin (adipoq)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein adiponectin (adipoq)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1165832

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CURNA, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20121218

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101ALI20121212BHEP

Ipc: C12N 15/63 20060101AFI20121212BHEP

Ipc: C07H 19/00 20060101ALI20121212BHEP

Ipc: C12Q 1/68 20060101ALI20121212BHEP

17Q First examination report despatched

Effective date: 20150203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150814

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1165832

Country of ref document: HK